Now Accepting Letters of Intent

View in Browser<https://protect-us.mimecast.com/s/GWG6CQW25Bck6P7LocPcPEK?domain=gcc02.safelinks.protection.outlook.com>
[Fb]<https://protect-us.mimecast.com/s/Sdz2CR605DuvrWNX5hPqR30?domain=gcc02.safelinks.protection.outlook.com>
[linkedin]<https://protect-us.mimecast.com/s/VcgzCVOk0KFxlyM8gIJLaIQ?domain=gcc02.safelinks.protection.outlook.com>
[Tw]<https://protect-us.mimecast.com/s/b2SECW6ljXu5jq08DhmQUqc?domain=gcc02.safelinks.protection.outlook.com>
[Ig]<https://protect-us.mimecast.com/s/i-nsCXD0k2IXnKmZOC9H6y5?domain=gcc02.safelinks.protection.outlook.com>
[AONN]<https://protect-us.mimecast.com/s/Qn-ZCYEnlNiL3l5XAh3tVoH?domain=gcc02.safelinks.protection.outlook.com>

The Academy of Oncology Nurse & Patient Navigators' (AONN+) National Navigation Acuity Team is seeking oncology programs to participate in a new Navigation Acuity Tool quality initiative. Interested programs should submit a letter of intent no later than December 5, 2022.

This quality initiative is the next step in the team's work to develop a standardized, validated, evidence-based Navigation Acuity Tool for oncology navigation programs. The tool will help address gaps that exist with current acuity tools, both in reliability and validity, while allowing oncology navigators to accurately characterize the complexity of their patients, aid in the allocation of navigation resources, and measure the effectiveness of navigation on patient outcomes. Astellas Pharma US, Inc., is sponsoring this body of work.

LEARN MORE<https://protect-us.mimecast.com/s/hqslCZ6omNu5MgzYQhN1szt?domain=gcc02.safelinks.protection.outlook.com>

SUBMIT LETTER OF INTENT<https://protect-us.mimecast.com/s/QdRxC1wnBPUMpG8XqTmu-VB?domain=gcc02.safelinks.protection.outlook.com>

We hope you'll join us in celebrating this exciting progress and consider taking part in the advancement of this valuable work.

Sincerely,

AONN+'s National Navigation Acuity Team

[https://d2geqc87xuuo99.cloudfront.net/email/AONN_2017/ConfEmailFormat_2017/AONNlogoSmall.png]<https://protect-us.mimecast.com/s/3FqkC31pKPupmKZv2Ujw0Wx?domain=gcc02.safelinks.protection.outlook.com>

Like Us on Facebook<https://protect-us.mimecast.com/s/nEw9C4xqYPuBJ5rxlHzCepV?domain=gcc02.safelinks.protection.outlook.com>

Connect with Us on LinkedIn<https://protect-us.mimecast.com/s/xObwC5yr1XFZ09A16HALvmm?domain=gcc02.safelinks.protection.outlook.com>

Follow Us on Twitter<https://protect-us.mimecast.com/s/J7iBC68vz4uromXJyiD0Jvw?domain=gcc02.safelinks.protection.outlook.com>

Follow Us on Instagram<https://protect-us.mimecast.com/s/Y8GIC73wW2CAmNLYZF481TD?domain=gcc02.safelinks.protection.outlook.com>

Copyright (c) 2022 Academy of Oncology Nurse & Patient Navigators. All rights reserved.

This e-mail was sent to xxxxxx@the-lynx-group.com<mailto:xxxxxx@the-lynx-group.com> by
Amplity Medical Communications, 1249 South River Road, Cranbury, NJ 08512, United States

Please do not respond to this message. Replies to this e-mail will be sent to an unmonitored e-mail address.
If you need support, please contact xxxxxx@amplity.com<mailto:xxxxxx@amplity.com>.

Forward to a Friend<https://protect-us.mimecast.com/s/4LAYC82xB0I6jq9gYcVJ3tz?domain=gcc02.safelinks.protection.outlook.com> | Unsubscribe<https://protect-us.mimecast.com/s/gSBlC9ryLPFkmq8j2cwKH1H?domain=gcc02.safelinks.protection.outlook.com>

Disclaimer: The information in this email and any attachments may contain proprietary and confidential information that is intended for the addressee(s) only. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution, retention or use of the contents of this information is prohibited. If you are a party with whom we have a contractual relationship, any information contained in this e-mail or any attachments is subject to the terms and conditions in the governing contract between us. If you are the intended recipient but our relationship is not governed by contract, then this email and its attachments are provided as-is and without warranty, and you may place no reliance thereon. If you have received this email in error, please immediately contact the sender and delete the email.